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To investigate whether thromboxane A2 is responsible 
for the initiation of vasospastic angina pectoris, throm•
boxane 8 2 levels were measured in the great cardiac vein 
and the arterial blood of 12 patients with clinically and 
angiographically proved vasospastic angina and thera•
peutic trials were performed with selective thromboxane 
A2 synthetase inhibitor OKY -046, all imidazole deriva•
tive. During ergonovine-provoked (11 cases) and spon•
taneous (1 case) anginal attacks, great cardiac vein 
thromboxane 8 2 increased from 121 ± 27 to 430 ± 382 
pglml (p < 0.05, n = 12), arterial thromboxane 8 2 
increased from 93 ± 18 to 122 ± 33 pg/ml (NS, n = 
12) and thromboxane 8 2 prodqction increased from 
3.18 ± I.S8 to 25.16 ± 22.32 ng/min (p < 0.05, 
n = 6). 
Subsequently, OKY -046, 400 mglday orally, was ad•
ministered to 7 of the 12 patients, while a continuous 
electrocardiogram was recorded on a dual channel Hol•
ter monitor during a 3 day placebo period and the 3 day 
The mechanism of vasospastic angina pectoris is unclear. 
Thromboxane A2 constricts vascular smooth muscle and has 
been considered a possible initiator or mediator of coronary 
artery spasm (I ,2); it also may play an important role in the 
genesis of acute myocardial ischemia (3-5), Increased levels 
of thromboxane B2 have been found in the peripheral (I) 
and coronary sinus (2) blood of patients with vasospastic 
angina, 
Whether this increase in thromboxane B2 levels is a cause 
or a result of vasospastic angina is unknown. In two previous 
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OKY -046 regimen. Although peripheral plasma throm•
boxane 8 2 levels decreased significantly from 98 ± 15 
to 12 ± 8 and 28 ± 10 pglml (1 and 6 hours after 
ingestion, respectively) (p < 0.05 for both), 6-keto-pros•
taglandin F la production in serum increased significantly 
from 0.48 ± 0.22 to 2.3 ± 0.72 (1 hour) and 1.8 ± 
0.46 nglml (6 hours) (p < 0.05 for both) during OKY-
046 administration. There were no significant differences 
in the number of ischemic episodes white patients were 
taking OKY-046 (7.8 ± 2.5 episodes daily) compared 
with placebo (7.5 ± 2.4). There was also no difference 
in the length of ischemic episodes, which averaged 
246 ± 81 secon<Js with placebo and 254 ± 78 seconds 
with OKY -046. Chest pain and nitroglycerin usage were 
not changed by OKY -046. 
Thus, thromboxane A2 is unlikely to initiate vaso•
spastic angina, but it may be released into the great 
cardiac vein during coronary vasospasm. 
(J Am Coli CardioI1986;7:25-9) 
studies (6,7) testing this hypothesis, aspirin was used to 
inhibit thromboxane A2 synthesis. Despite the decreased 
thromboxane B2 levels induced by aspirin administration, 
attacks of vasospastic angina did not change significantly. 
Thus, the authors (6,7) concluded that thromboxane A2 is 
unlikely to cause vasospastic angina and is probably not 
responsible for the initiation of coronary vasospasm, but 
may be released during coronary vasospasm. However, there 
is a possibility that aspirin, a cyclooxygenase inhibitor (8), 
concomitantly depresses prostacyclin synthesis in the vessel 
wall, which may lead to these negative results. 
In this study, the role of thromboxane A2 in the initiation 
of vasospastic angina was investigated using a more specific 
blocker of thromboxane A2 synthesis, a selective throm•
boxane synthetase inhibitor, OKY-046. 
Methods 
Patient group. Twelve male patients aged 40 to 74 years 
(mean 52) were studied. The clinical diagnosis of vaso•
spastic angina was established on the basis of frequent, 
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recurrent episodes of chest pain, occurring mainly at rest 
and associated with transient ST segment elevation (>0.2 
m V). Each patient underwent continuous electrocardio•
graphic monitoring so that the frequency of ischemic epi•
sodes cquld be assessed objectively. The electrocardio•
graphic lead showing the most evident ST segment changes 
during the ischemic episode was selected for this purpose. 
All patients had four or more episodes of transient myo•
cardial ischemia daily documented by typical transient isch•
emic changes. 
(treadmill) and five had positive results for different levels 
of external work load. Only one patient (Case 12) with a 
75% stenotic lesion of the left anterior descending coronary 
artery had exercise-induced ST segment elevation in the 
morning, presumably caused by coronary spasm. The an•
giographic appearance of the artery or arteries involved by 
spasm and other clinical data are shown in Table 1. 
All patients performed a symptom-limited exercise test 
Cardiac catheterization and blood sampling. Coronary 
arteriography, performed in all patients by the Sones tech•
nique, showed variable degrees of atherosclerotic disease, 
from normal coronary arteries to triple vessel disease. Dur-
Table 1. Summary of Data in 12 Patients 
Case 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Age 
(yr) & 
Sex 
Coronary Arteriogram* 
Control Spasm ECG at Rest 
53M LAD 90% LAD 100% Normal 
40M Normal 
50M 
47M 
LAD 90% 
LCx 75% 
RCA 75% 
LAD 25% 
LAD 90% Normal 
LAD 99% 
LCx 75% 
RCA 75% 
LAD 100% 
ST depression 
in leads 
Vs, V6 
ST depression 
in lead V4 
41 M LAD 50% LAD 99% Normal 
LCx 50% LCx 50% 
59M LCx 75% LCx 75% Normal 
LAD 100% 
52M Normal LAD 100% Normal 
74M Normal LAD 90% Normal 
RCA 100% 
67M Normal LAD 100% Normal 
LCx 100% 
61M LAD 50% LAD 100% Normal 
ECG During 
Attack 
ST elevation 
in leads 
V2 toYs 
ST elevation 
in leads 
VI, V2 
ST elevation 
in leads 
V4 to V6 
ST elevation 
in leads 
VI to V6 
ST elevation 
in leads 
V4 to V6 
ST elevation 
in leads 
V2 to V4 
ST elevation 
in leads 
VI to V4 
ST elevation 
in leads 
V 2, II, III, 
aVF 
ST elevation 
in leads 
VI to V6 
ST elevation 
in leads 
V2 to V4 
II ~8M LAD 50% LAD 99% ST depression ST elevatlon 
12 
Mean 
± SO 
55M 
LCx 50% 
RCA 50% 
LAD 75% 
LCx 50% 
RCA 50% 
LAD 90% 
in leads 
Vs, V6 
ST depression 
In leads 
V2 , V3 
in leads 
VI to V4 
ST elevation 
in leads 
V2 to Vs 
PTXB2 (AlG) (pg/ml) 
Control Spasm 
87/93 136/325 
1201136 1261204 
92/100 140/350 
104/180 1201210 
92/100 1201250 
Great Cardiac 
Vein Flpw 
(mllmin) 
Control Spasm 
91.3 55.0 
45/111 12011,040 72.0 5.0 
58/132 102/1,400 78.0 
1091167 110/203 
90/116 1221210 
62/92 641150 
108/104 94/176 
102/115 210/642 
93.11120.5 122/430 
18.2127.2 32.9/382 
72.1 
87.0 
79.0 
79.7 
7.2 
4.8 
52.0 
50.0 
6.1 
29.9 
23.6 
TXB2 Production 
(ng/min) 
Control Spasm 
0.73 
4.75 
5.77 
4.18 
2.61 
,.03 
3.18 
1.88 
7.15 
46.00 
62.30 
4.84 
4.30 
26.35 
25.16 
22.32 
*Values indicate percent luminal stenosis. A = aorta; pCG = electrocardiogram; G = great cardIac vein; \.-AD = left anterior desfending coronary 
artery; LCx = left circumflex coronary artery; M = male; PTXB2 = plasma thromboxane B2; RCA = right coronary artery; TXB2 = thromboxane 
B2 . 
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ing angiography, coronary vasospasm of the left anterior 
descending artery was documented in all patients. It was 
provoked by ergonovine administration in II patients and 
occurred spontaneously in 1 patient. A 7F coronary sinus 
flow catheter (Webster Co.) was positioned in the great 
cardiac vein with its position confirmed by the injection of 
constrast medium. Great cardiac vein flow was determined 
using a Webster model CBA-21O flow meter (9). The re•
producibility of the flow data was 8.50;( (Coefficient of 
variation, n = 10). 
Five milliliters of blood was withdrawn simultaneously 
from the great cardiac vein and the sinus of Valsalva into 
a plastic syringe and transferred into glass tubes containing 
I mM of ethylenediaminetetraacetic acid (EDT A) and 0.1 
mM of indomethacin. Samples were centrifuged at 1,500 g 
for 20 minutes. The plasma was frozen and kept at ~- 80°C 
until assay. After the control blood sampling and coronary 
arteriogram, ergonovine was administered intravenously in 
a peripheral vein as bolus injections of 0.05, 0.05, 0.1 and 
0.2 mg every 3 minutes until induction of typical angina or 
up to a maximal total dose of 0.4 mg. When angina was 
induced, a coronary angiogram was taken immediately after 
blood sampling and measurement of great cardiac vein flow. 
After the arteriogram, the ~pasm was promptly relieved by 
intracoronary administration of nitrates. All patient~ gave 
informed consent for the study. 
Methods of assay. The methods of determining plasma 
thromboxane B2 leveL inhibItion of thromboxane B2 pro•
duction in serum and 6-keto-prostaglandin FIe> production 
in serum and the specificity of the assays were as previously 
reported (10). Thromboxane B2 productIOn (ng/min) was 
measured as (great cardiac vein thromboxane B2 arterial 
thromboxane B2) x great cardiac vem flow (mllmin). 
Protocol. Patients were hospitalized throughout the study 
period, which consisted of a 3 day trial of placebo and a 3 
day regimen of oral OKY-046, 100 mg every 6 hours, 
performed in a double-blind fashion. Throughout the study. 
two electrocardiographic leads were continuou~ly recorded 
on a dual channel Holter monitor (Avionics 660 A). Re•
cordings were obtained m the hospital after all antianginal 
treatment had been discontinued for at least 24 hours. Only 
sublingual nitroglycerin was given if required. Patients were 
carefully monitored by medical and nursing personnel. 
Electrocardiographic tapes were analyzed for episodes of 
1 mm or greater ST segment elevation (no patient had ST 
depression) lasting 30 seconds or longer and not accounted 
for by positional change. Patients kept a diary of the fre•
quency and severity of chest pain and use of nitroglycerin. 
The nitroglycerin was used for episodes lasting more than 
I minute. The average daily number and length of episodes 
of ST elevation during the placebo period were compared 
with those during the entire OKY -046 treatment period using 
analysis of variance and paired Student's f test~. The Holter 
recording was interpreted by an investigator unaware of 
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which drug was being administered to the patient. Blood 
samples were drawn from a peripheral vein during the period 
of placebo and OKY -046 administration at 1 and 6 hours 
after ingestion on the second day of each triaL 
Test drug (11-13). OKY-046 «E)-3-[4-imidazolyl•
methyl]phenyl-2-propenoic acid hydrochloride monohy•
drate) was supplied by Kissei Pharmaceutical Company 
(Matsumoto, Japan) and Ono Pharmaceutical Company 
(Osaka, Japan). The 50% inhibitory concentration (ICso) on 
the thromboxane B2 generation in serum was 4 mg. 
Statistics. Values were expressed as mean ± SO. A 
paired t test with one-way analysis of variance was per•
fonned for each sample. A probability (p) value of less than 
0.05 was considered significant. 
Results 
Thromboxane B2 during vasospasm. During ergono•
vine-provoked (II cases) and spontaneous (I case, Case 8) 
anginal attacks, there were the following changes: great 
cardiac vein thromboxane B2 increased from 121 ± 27 to 
430 ± 382 pg/ml (p < 0.05, n = 12), arterial thromboxane 
B2 increased from 93 ± 18 to 122 ± 33 pg/ml (NS, n = 
12) and thromboxane B 2 production increased from 3.18 ± 
1.88 to 25.16 ± 22.32 ng/min (p < 0.05, n = 6). All 
patients produced thromboxane B2 during coronary spasm. 
Relations among aortic, great cardiac vein and pe•
ripheral thromboxane B2 levels. At cardiac catheteriza•
tion, 20 minutes after injection of OKY-046, 100 mg, the 
peripheral. aortic and great cardiac vein levels of throm•
boxane B2 decreased: peripheral thromboxane B2 from 92 
± 13 to 17 ± 25 pg/ml (p < 0.01, n = 7); aortic throm•
boxane B2 from 94 ± 15 to 21 ± 14 pg/ml (p < 0.01); 
Figure 1. Effect ofOKY-046 (0) on number of ischemic episodes 
daily (left) and mean length of ischemic episodes (right) compared 
with placebo (pl. Each value is the mean of 3 days. 
rN.S.I .N.S .• 
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and great cardiac vein thromboxane 8 2 from 112 ± 28 to 
28 ± 14 pg/ml (p < 0.01). 
Administration of OKY-046. Subsequently, we ad•
ministered OKY-046, 400 mg/day (100 mg orally every 6 
hours), to seven patients (Cases l, 2, 3, 5, 6, 7 and 10) 
and recorded a continuous electrocardiogram on a dual chan•
nel Holter monitor for 3 days before (placebo) and 3 days 
after ingestion. Peripheral plasma thromboxane 8 2 levels 
decreased significantly from 98 ± 15 to 12 ± 8 pg/ml (I 
hour after ingestion) and to 28 ± 10 pg/ml (6 hours after 
ingestion) (p < 0.05 for both); 6-keto-prostaglandin FIll' 
production in serum increased significantly from 0.48 ± 
0.22 to 2.3 ± 0.72 ng/ml (after I hour) and to 1.8 ± 0.46 
ng/ml (after 6 hours) (p < 0.05 for both) during OKY-046 
administration. In all patients, OKY-046 treatment sub•
stantially decreased peripheral thromboxane 8 2 levels. 
However, there was an average of 7.5 ± 2.4 ischemic 
episodes daily while patients were receiving placebo and 
7.8 ± 2.5 episodes daily while they were receiving OKY-
046 (Fig. 1, left). There was also no significant difference 
between the length of ischemic episodes during the two 
regimens; the duration of ST elevation averaged 246 ± 81 
seconds with placebo and 254 ± 78 seconds with OKY-
046 (Fig. I, right). The frequency of chest pain was 4.2 ± 
2.5 episodes daily with placebo and 3.8 ± 1.5 episodes 
daily with OKY-046. The use of nitroglycerin (7.2 ± 1.5 
tablets daily with placebo versus 6.8 ± 1.0 tablets daily 
with OKY-046) was not altered. 
Discussion 
Thromboxane B2 during coronary vasospasm. The 
mechanism of significantly increased levels of thromboxane 
8 2 in the great cardiac vein during vasospasm may be as 
follows: arachidonic acid is liberated from the phospholipid 
in the cell membrane of the coronary artery and is trans•
formed into prostaglandin O2 and prostaglandin H2, which 
are transferred to platelets where thromboxane A2 is formed. 
It is not known whether this increased thromboxane 8 2 is 
a cause or a result of vasospastic angina. 
Inhibition of thromboxane B2 production by aspirin 
and OKY-046. Two previous studies (6,7) have reported 
on the role ofthromboxane Az in vasospasm. In both studies 
aspirin was found to lower thromboxane 8 2 levels in patients 
with vasospastic angina but to have no effect on the fre•
quency of anginal attacks. The authors concluded that 
thromboxane A2 is not related to the initiation of the va•
sospastic episode caused by coronary spasm. However, as•
pirin can concomitantly prevent the production of prosta•
cyclin in the vessel wall through acetylation of cyclooxygenase 
(8) and, therefore, aspirin may increase the vasospastic ten•
dency in the vessel wall. In fact, Miwa et al. (14) reported 
on a patient whose variant angina was aggravated by high 
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dose oral aspirin, 4 g/day. Thus, the inhibition of prosta•
cyclin synthesis might be partially responsible for the pre•
viously reported results (6,7). 
We employed an oral selective thromboxane A2 synthe•
tase inhibitor, OKY-046, 400 mg/day, instead of aspirin. 
This compound decreased peripheral thromboxane 8 2 lev•
els, but it did not affect the number or duration of ischemic 
episodes in patients with vasospastic angina who have fre•
quent anginal attacks. 
Mechanism of action. When OKY -046 is administered 
to humans, there are changes that may occur in prostaglandin 
metabolism. The expected beneficial effects are both inhi•
bition of thromboxane A2 production and increased pros•
tacyclin production through conversion from stored pros•
taglandin H2. Changes in plasma 6-keto-prostaglandin FIll' 
in humans cannot be evaluated (10,15). However, serum 
6-keto-prostaglandin FIll' production was found to increase 
with OKY-046, a selective thromboxane A2 synthetase in•
hibitor, as previously reported for OKY-1581 in humans 
(10). Although prostacyclin may be increased in patients by 
OKY-046 administration, this increase may not affect the 
frequency or duration of anginal attacks. Indeed, Chierchia 
et al. (16) reported that in eight of nine patients with variant 
angina, prostacyclin infusion could not prevent vasospastic 
angina. Thus, the hypothesis that coronary spasm results 
from a local imbalance between thromboxane A2 and pros•
tacyclin seems to be losing its appeal. 
We express our appreciation to Daniel Mrozek for help with the preparatIon 
of the manuscript. 
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